The purpose of this study is to better understand the effects of the chemotherapy medication
bortezomib on cancer cells. The investigators are therefore taking blood and bone marrow
samples from patients with myeloma who are receiving bortezomib to see if the investigators
can detect autophagy in the myeloma cells from the bone marrow and in immune cells in the
blood. Subjects are eligible if their doctor is planning to treat them with bortezomib for
the first time for their myeloma.